Lineagen racks up $15.8 mln Series C
Salt Lake City-based Lineagen Inc, a molecular diagnostics company focused on childhood development disorders, has closed $15.8 million in Series C funding. The investors included HealthQuest Capital, Petra Capital Partners, Mountain Group Partners. Sanderling Ventures, Signal Peak Ventures, PrairieGold Venture Partners, Mesa Verde Venture Partners and KickStart Ventures. In addition to the funding, Dr. David S. Kabakoff, a partner at HeathQuest Capital and David Fitzgerald of Petra Capital have been added to Lineagen's board of directors.
18 February 2015•4 mins read
